REG - Kromek Group PLC - Issue of Equity, TVR & Extension of Options

KromekAnnouncement

30/04/2026 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260430:nRSd6462Ca&default-theme=true

RNS Number : 6462C  Kromek Group PLC  30 April 2026

30 April 2026

 

Kromek Group plc

("Kromek", the "Company" or the "Group")

 

Issue of Equity, Total Voting Rights and Extension of Options

 

Kromek (AIM: KMK), a global detection company delivering best-in-class
solutions for the advanced imaging and CBRN detection markets, announces that
it has issued and allotted 40,000 ordinary shares of 1p each in the Company
("Ordinary Shares") following the exercise of options by a former employee
who retired from the Company and is classified as a good leaver.

 

The Company also announces that it has agreed to extend the exercise period of
certain share options granted to Berry Beumer, an Executive Director of the
Company, as follows:

 

 Director      Number of options  Exercise price  Grant date     Original expiry date  New expiry date
 Berry Beumer  150,000            1.0p            29 April 2021  30 April 2026         31 May 2026

 

The extension was granted due to the original expiry date coinciding with a
close period and the PDMR status of Mr Beumer would prevent him from
potentially exercising these options.

 

Total voting rights

 

Application has been made to the London Stock Exchange for the 40,000 Ordinary
Shares to be admitted to trading on AIM ("Admission") and it is expected that
Admission will become effective at 8 a.m. on or around 7 May 2026. The new
Ordinary Shares will rank pari passu with the existing Ordinary Shares in the
Company.

 

Following Admission, the total number of Ordinary Shares in issue will be
655,136,840. This figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the share capital of the
Company under the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.

 

 

Enquiries

 

 Kromek Group plc
 Arnab Basu, CEO                                                        +44 (0)1740 626 060

 Claire Burgess, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)        
 Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance            +44 (0)20 7220 0500

 Andrew Burdis - ECM

 Michael Johnson - Sales

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury                                           +44 (0)20 4582 3500

 

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to
the global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation and
solid-state readout technology, are primarily used to protect critical
infrastructure, events, personnel and urban environments from the threat of
'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCIMMJTMTTJBFF



            Copyright 2019 Regulatory News Service, all rights reserved